Due to the inability of current therapeutics to cure the majority of B-cell NHLs and myeloid neoplasms and the eventual development of drug resistance, the therapeutic targeting of IRAK-4 is a merited treatment strategy. The gene discussed is IRAK4; the disease is B-cell non-Hodgkin lymphoma.